复必泰新冠疫苗内地上市仍在审批沟通中

一图看懂丨3月24日上海疫情防控发布会，这些信息值得关注。（一财）","multimedia":{"img_url":["https://n.sinaimg.cn/zhibo/500/w1000h5100/20220324/1f60-ef3feba6e5116e13a508e59660045293.jpg"]},"commentid":"live:finance-152-2597439:0","compere_id":0,"creator":"yongsheng6@staff.sina.com.cn","mender":"yongsheng6@staff.sina.com.cn","create_time":"2022-03-24 12:20:37","update_time":"2022-03-24 12:20:45","is_need_check":"0","check_time":"1970-01-01 08:00:01","check_status":"1","check_user":"","is_delete":0,"top_value":0,"is_focus":0,"source_content_id":"0","anchor_image_url":"","anchor":"直播员","ext":"{"stocks":[],"needPush":false,"needAIPush":false,"needCMSLink":true,"needCalender":false,"needProvince":"u4e0au6d77","docurl":"https:\/\/finance.sina.com.cn\/7x24\/2022-03-24\/doc-imcwiwss7845800.shtml","docid":"mcwiwss7845800"}","old_live_cid":"0","tag":[{"id":"110","name":"疫情"}],"like_nums":0,"comment_list":{"list":[],"total":0,"thread_show":0,"qreply":0,"qreply_show":0,"show":0},"docurl":"https://finance.sina.cn/7x24/2022-03-24/detail-imcwiwss7845800.d.html","rich_text_nick_to_url":[],"rich_text_nick_to_routeUri":[],"compere_info":""},{"id":2597438,"zhibo_id":152,"type":0,"rich_text":"【复必泰新冠疫苗内地上市仍在审批沟通中】复星国际执行董事、联席CEO陈启宇在今日举行的复星国际线上业绩说明会上透露，由复星医药和德国百欧恩泰(BioNTech)合作开发的mRNA新冠疫苗复必泰在中国内地上市的审批工作仍在积极沟通中。陈启宇透露，截至2022年2月末，该款疫苗于港澳台地区已累计接种超2000万剂，销售收入超过5亿美元。进入2022年港澳地区还在加速后续疫苗接种。（一财）